Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep ...

The statement also notably included a "first-line" call out for icosapent ethyl , a novel agent approved in December 2019 for routine use in U.S. patients, including those with CAD and T2DM as ...

Populations of African descent are at the forefront of the worldwide epidemic of type 2 diabetes mellitus (T2DM). Here, Anne Sumner and colleagues discuss issues related to the diagnosis and ...

Compared to placebo, canagliflozin reduced the risk of the composite primary endpoint (cardiovascular mortality, nonfatal MI, nonfatal stroke) by 14% (HR: 0.86; 95% CI: 0.75-0.97).

CAD: More Common in Patients with T2DM and Heterozygous Familial Hypercholesterolemia? —That was the question at the center of a Chinese study that assessed patients with heterozygous familial ...

Out of the 100 individuals diagnosed with T2DM, ultrasonography confirmed NAFLD in 50 patients, who were categorized as Group A, while the remaining 50 patients without fatty liver comprised Group ...

METHODOLOGY: Investigators analyzed data from clinical and laboratory tests, FibroScan, and liver ultrasonography for 154 patients (average age, 51 years; 59.7% men; 42.9% with T2DM) with MASLD in ...

In addition to T2DM, HTD1801 efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial, and a global multicenter Phase 2b ...

Conclusions: T2DM patients with established CVD or CVD risk factors are at significant risk for mortality and CVD events. They incur high healthcare utilization and costs, ...

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), sulfonylureas seem to increase levels of free fatty acids (FFA) and triglycerides (TG) and lower low-density lipoprotein ...